Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

JNJ 98.09 +0.63 (0.65%)
price chart
Johnson & Johnson diabetes drug effective in high risk patients
An experimental treatment for type 2 diabetes developed by Johnson & Johnson proved effective at reducing blood sugar in patients on long-term insulin therapy and at high risk for heart problems, according to a study presented on Tuesday.
J&J's Global Creative Review Nears Finish
Johnson & Johnson is close to concluding its global review of creative responsibilities for its over-the-counter brands and sources expect the bulk of the business to be consolidated at three roster shops: DDB, BBDO and JWT.
Johnson & Johnson Agrees to Settle Five Rispersal Suits
Oct. 4 (Bloomberg) -- Johnson & Johnson agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.
Ex-FDA chief David Kessler says J&J broke the law in promoting Risperdal  Philadelphia Inquirer (blog)
Tylenol and the Legacy of J&J's James Burke
This post is in partnership with Knowledge@Wharton, the online research and business analysis journal of the Wharton School of the University of Pennsylvania.
Johnson & Johnson facing massive class action
Medical giant Johnson & Johnson is facing its third class action in Australia in as many years, with a case filed in the Federal Court yesterday which relates to a product called transvaginal mesh.
Johnson & Johnson third-quarter profit hit by charges, currency fluctuations
Johnson & Johnson posted third-quarter earnings that beat analysts' estimates, while executives said to expect a brighter future from the company as it preps a pipeline of promising new drugs, expands into new markets overseas and positions itself to ...
Johnson & Johnson Tops Street in 3Q, Lifts Outlook  Fox Business
Johnson & Johnson earnings exceed expectations  Financial Post (blog)
The Good, The Bad And The Ugly: Johnson & Johnson
They have all been recalled by Johnson & Johnson (NYSE:JNJ) between 2009 and 2012 for everything from the relatively inconsequential (Motrin caplets dissolving too slowly) to the very serious (bacterial contamination in Infant's and Children's Tylenol).
Uncertainty At Johnson & Johnson Creates Risk
At minimum, current shareholders should hold Johnson & Johnson (NYSE:JNJ) until the next earnings release; interested investors should initiate a position this month.
Strong earnings reports from Mattel, Goldman Sachs, Johnson & Johnson help ...
Unexpectedly strong earnings reports from heavyweights like Mattel and Johnson & Johnson streamed in on Tuesday, helping fuel a rally on Wall Street.
Stocks Shoot Higher on 3rd Quarter Profits; Mattel Jumps  DailyFinance
Gores Group to Buy Johnson & Johnson Unit
The Gores Group on Monday said that it has agreed to acquire the maker of a medical device that's used to treat blood cancer from a unit of New Jersey health care conglomerate Johnson & Johnson. Therakos is a 25-year-old company based in Raritan, N.J ...
Gores Group to buy Therakos from Ortho-Clinical Diagnostics